Compare SINT & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SINT | SYBX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.2M |
| IPO Year | 2014 | N/A |
| Metric | SINT | SYBX |
|---|---|---|
| Price | $3.98 | $1.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 80.0K | 68.9K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $80.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.71 | $0.90 |
| 52 Week High | $7.36 | $1.96 |
| Indicator | SINT | SYBX |
|---|---|---|
| Relative Strength Index (RSI) | 59.65 | 19.74 |
| Support Level | $3.30 | $1.01 |
| Resistance Level | $4.23 | $1.73 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 80.88 | 5.56 |
SINTX Technologies Inc is a ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming a renowed ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have good bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.